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Objectives The purpose of this study was to assess the impact of manual versus automated contrast
injection on renal complications in patients undergoing percutaneous coronary intervention (PCI).
Background Contrast volume is a major modiﬁable risk factor for contrast-induced nephropathy
(CIN). Automated contrast injector systems (ACIS) are believed to be associated with a reduction in
the total volume of contrast media use.
Methods We compared the outcome of 60,884 patients who underwent PCI at 28 hospitals in
Michigan in 2008 to 2009 and assessed the outcome of those treated at hospitals that did not use
ACIS (n  24) and compared them with those that used ACIS (n  4). Propensity matching was
used to adjust for baseline differences.
Results The use of ACIS was associated with a statistically signiﬁcant albeit clinically small differ-
ence in the average volume of contrast media use (mean 199  84 ml vs. mean 204  82 ml, p 
0.0001) with no difference in proportion of patients exceeding contrast volume/calculated creatinine
clearance ratio of 3 (28.4% vs. 29.1%, p  0.19). There was no difference in the incidence of CIN
(3.11% vs. 3.42%, p  0.15) or new need for dialysis (0.30% vs. 0.33%, p  0.54), and these differ-
ences remained nonsigniﬁcant in propensity matched analysis. In fully adjusted, multivariate logistic
analysis, patients treated with ACIS remained as likely to develop CIN (odds ratio: 0.96, 95% conﬁ-
dence interval: 0.83 to 1.11, p  0.56) or new need for dialysis (odds ratio: 0.83, 95% conﬁdence
interval: 0.54 to 1.28, p  0.40).
Conclusions Compared with hospitals using manual injection, institutions having ACIS used slightly
less amount of contrast with no reduction in CIN. Use of ACIS is unlikely to impact contrast-induced
renal complications in patients undergoing PCI. (J Am Coll Cardiol Intv 2013;6:399–405) © 2013 by
the American College of Cardiology Foundation
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400Contrast-induced nephropathy (CIN) is a common com-
plication in patients undergoing percutaneous coronary
intervention (PCI) and is associated with increased morbid-
ity, mortality, and healthcare expense (1–3). Multiple strat-
egies have been advocated for prophylaxis of CIN, but the
only proven strategies are adequate hydration, minimization
of contrast dose, and the use of iso-osmolar or certain
low-osmolar contrast media (4–8). The impact of contrast
dose has been evaluated in multiple studies, and patients
receiving high doses of contrast seem to be at greater risk of
CIN and need for dialysis. Although multiple different
thresholds have been explored for estimating safe dose of
contrast media, there seems to be no dose of contrast that is
free of risk, and a strategy of limiting contrast with as little
as safely possible has been advocated (9). Practical strategies
to limit contrast media include use of biplane angiography,
selective avoidance of left ventriculography, and minimiza-
tion of coronary injections. Automated contrast injector
systems (ACIS) have been promoted as a strategy to reduce
contrast use and are assumed to be effective in reducing
renal complications in patients
undergoing contrast-based pro-
cedures. However, this assump-
tion is based on small single-
center studies, and there is a
paucity of data on the clinical
effectiveness of ACIS with re-
spect to reducing contrast use
and associated improvement in
clinical outcome (10–12). The
goal of our study was to assess
the clinical utility of ACIS
across a broad population of pa-
tients undergoing PCI in the
Blue Cross Blue Shield of Michigan Cardiovascular Con-
sortium (BMC2)—a large multicenter quality improvement
collaborative.
Methods
Data sources and study population. We examined the out-
come of 60,884 patients who were treated in 2008 to 2009
at the hospitals participating in the BMC2 and assessed the
outcome of those treated at hospitals that did not use ACIS
(n  24) and compared them with those that used ACIS
n  4). Hospitals that initiated use of ACIS during the
tudy period or used both ACIS and manual injection were
xcluded (n  5). The details of the BMC2 and its data
ollection and auditing process have been described previ-
usly (13). The BMC2 is a physician-run quality improve-
ent collaborative that is supported by but independent of
he funding agency, Blue Cross Blue Shield of Michigan. A
hysician advisory committee is responsible for setting the
Abbreviations
and Acronyms
ACIS  automated contrast
injector systems
CABG  coronary artery
bypass grafting
CIN  contrast-induced
nephropathy
NRD  nephropathy
requiring dialysis
PCI  percutaneous
coronary interventionuality goals and developing quality improvement effortsithout any input from or sharing of data with the study
ponsor. Procedural data on all consecutive patients under-
oing PCI at participating hospitals are collected with
tandardized data collection forms. Baseline data include
linical, demographic, procedural, and angiographic charac-
eristics as well as medications used before, during, and after
he procedure and in-hospital outcomes. All data elements
ave been prospectively defined, and the protocol is ap-
roved by local institutional review boards at each hospitals.
n addition to a random audit of 2% of all cases, medical
ecords of all patients undergoing multiple procedures or
oronary artery bypass grafting (CABG) and of patients
ho died in the hospital are reviewed routinely to ensure
ata accuracy. The study population for this analysis in-
luded all consecutive patients who underwent PCI between
anuary 1, 2008, and December 31, 2009. Patients who were
lready on a dialysis regimen at the time of the procedure or
hose with missing serum creatinine pre- or post-procedure
ere excluded from outcome analysis. The type of contrast
edia and hydration protocols used were as per the operator
reference guided by institutional policy and practice.
Study endpoints. Our study had 3 endpoints for this anal-
sis: procedural contrast volume, CIN, and nephropathy
equiring dialysis (NRD). Contrast-induced nephropathy
as defined as impairment in renal function resulting in
0.5 mg/dl absolute increase in serum creatinine from
aseline (14). Baseline creatinine was collected within 1
onth of the procedure. Among patients who had multiple
ssessments of serum creatinine in the 30 days before the
rocedure, the value closest to the time of the procedure was
onsidered as the baseline value. Peak creatinine was defined
s the highest value of creatinine in the week after the
rocedure and was ascertained as per local clinical practice.
eak creatinine was collected at least 1 day post-procedure
ut varied, depending on length of stay. Nephropathy
equiring dialysis was defined as new, unplanned need for
emodialysis during the hospital stay due to worsening of
enal function after PCI.
Statistical analysis. We separated patients into 2 categories:
those treated at institutions that used ACIS universally; and
those treated at institutions that did not have ACIS.
Differences in discrete variables between patients treated
with ACIS and those who were not were evaluated by the
chi-square test and Fisher exact test. Continuous variables
were expressed as mean  SD, and discrete variables were
expressed as frequency counts and percentages. Continuous
variables were analyzed with the Student t test.
We compared the difference in total contrast volume and
the proportion of patients exceeding a contrast volume/
calculated creatinine clearance ratio of 3 among patients
treated with ACIS versus those not treated with ACIS. We
assessed the independent impact of ACIS use on outcome
by multivariable adjustment for differences in baseline fac-
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401tors (but excluding contrast volume). Separate models were
developed for CIN and NRD.
Furthermore, to account for the multiple differences
between patients treated with and patients treated without
ACIS, we used propensity matching. A propensity score for
receiving ACIS was calculated with a non-parsimonious
Table 1. Baseline Characteristics of Patients Tre
Manual Contrast Injection
Variable Type
Demographic
Age, yrs
Age 60–69 yrs
Age 70–79 yrs
Age 80 yrs
Female
Overweight
Obese
Historical
Current smoking
Creatinine clearance 60–89
Creatinine clearance 30–59
Creatinine clearance 30
Hypertension
MI
Diabetes mellitus
Congestive heart failure
Extracardiac vascular disease
Signiﬁcant valve disease
Renal failure and dialysis
Gastro-intestinal bleeding
Atrial ﬁbrillation
Cardiac arrest
History of prior PCI
Prior CABG
Chronic obstructive pulmonary disease
MI present (7 days prior)
Acute MI (24 h prior)
Cardiogenic shock
History of prior cardiac arrest
Ventricular tachycardia/ﬁbrillation
Emergent PCI
Laboratory
Baseline creatinine, mg/dl
Baseline creatinine 1.5 mg/dl
Peak creatinine, mg/dl
Baseline hemoglobin, g/dl
Anemia
Ejection fraction
Ejection fraction 50%
Total ﬂuoroscopy time, min
Values are mean SD or %.ACISautomatedcontrast injector systems;CABGcoronaryarterybypasslogistic regression model created from several pre-
procedural patient characteristics. These patient character-
istics included age, sex, serum creatinine, anemia, calculated
creatinine clearance rate, smoking status, history of hyper-
tension, diabetes, prior myocardial infarction, congestive
heart failure, prior coronary revascularization (PCI or
ith ACIS Versus Those Treated With
CIS
uency
9,995)
Manual Injection
Frequency
(n  50,889) p Value
 12.1 64.6 12.2 0.02
.7 29.4 0.16
.5 22.9 0.0007
.4 12.9 0.0001
.0 34.9 0.0003
.3 35.1 0.78
.5 46.2 0.01
.6 26.8 0.0001
.0 29.9 0.82
.1 19.2 0.01
.9 2.2 0.04
.7 85.0 0.0006
.8 36.2 0.0001
.3 36.9 0.0001
.4 17.3 0.0001
.9 27.3 0.004
.81 4.41 0.0001
.66 2.13 0.003
.37 1.33 0.74
.86 10.94 0.002
.59 1.30 0.02
.5 47.6 0.0001
.7 20.2 0.0003
.2 20.2 0.0001
.5 30.7 0.0005
.4 18.1 0.0001
.48 1.65 0.0001
.77 1.46 0.02
.36 1.09 0.02
.0 14.1 0.01
 0.9 1.17 1.0 0.20
.0 11.4 0.19
 0.9 1.22 1.2 0.03
 1.9 13.4 1.9 0.0001
.9 30.7 0.0001
 12 50.9 12 0.0001
.1 31.6 0.0001
 10.0 14.8 11.2 0.0001ated W
A
Freq
(n 
64.3
28
24
11
33
35
47
28
30
18
1
83
32
33
14
25
2
1
1
9
1
41
18
16
32
20
2
1
1
15
1.14
11
1.16
13.6
26
51.3
29
13.5grafting;MImyocardial infarction; PCIpercutaneouscoronary intervention.
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402CABG), atrial fibrillation, peripheral vascular disease, his-
tory of stroke or transient ischemic attack, chronic obstruc-
tive pulmonary disease, left ventricular ejection function,
and acuity of cardiac illness at presentation. Greedy match-
ing technique was then used to match a patient receiving
ACIS to a patient with the nearest propensity score who did
not receive ACIS to permit adequate comparison of similar
patients. Matching adequacy was confirmed by calculating
the standardized differences for baseline variables among the
matched subset with a standardized difference of 10%
suggesting adequate matching and by assessing for differ-
ences in outcomes that would not be expected to be
influenced by ACIS use (vascular complications and need
for CABG). The study endpoints were then compared
within this propensity-matched cohort with paired testing
(15). We further evaluated differences in outcomes among
several key, high-risk patient subgroups, including patients
with abnormal renal function at baseline, diabetes, and
anemia and patients treated with low osmolar contrast
media. Glomerular filtration rate was estimated with the
Modification of Diet in Renal Disease equation (16). The
SAS software (version 9.2, SAS, Cary, North Carolina) was
used for all analyses.
Results
Our study cohort comprised 60,884 patients, of whom
9,995 were treated at institutions with ACIS, and 50,889
were treated at institutions that did not use ACIS. The
baseline demographic characteristics, comorbidities, and
select laboratory variables are presented in Table 1. Patients
treated with ACIS were slightly younger, less likely to have
Figure 1. Unadjusted Outcomes
Key unadjusted outcomes of patients treated with automated contrast injecto
CABG  coronary artery bypass grafting; CIN  contrast-induced nephropathy.hypertension, and more likely to have had a recent myocar-
dial infarction. There was no difference in the baseline
serum creatinine. The fluoroscopic time was shorter in
patients treated with ACIS.
The mean contrast volume in the ACIS group was 199
4 ml compared with a mean of 204  82 ml in patients
treated without ACIS (p  0.0001). The proportion of
patients exceeding contrast volume/calculated creatinine
clearance of 3 was similar at institutions using ACIS (28.4%
vs. 29.1%, p  0.19). There was no difference in the
incidence of CIN (3.11% vs. 3.42%, p  0.15) or NRD
(0.30% vs. 0.33%, p  0.54). No difference was noted with
respect to in-hospital mortality or need for CABG (Fig. 1).
After multivariate adjustment, there was no difference in
the odds of CIN (odds ratio: 0.96, 95% confidence interval:
0.83 to 1.11, p  0.56) or new need for dialysis (odds ratio:
0.83, 95% confidence interval: 0.54 to 1.28, p  0.40) with
ACIS compared with no ACIS.
Propensity-matched analysis. The baseline comparison of
he propensity-matched cohort is provided in Table 2. The
groups (ACIS vs. no ACIS) were wellmatched, and no
ajor differences were noted with respect to any of the
ariables. The use of ACIS was associated with a similar
ncidence of CIN (3.17% vs. 2.91%, p  0.34) and a similar
ncidence of NRD (0.28 vs. 0.18, p  0.17). There was no
ifference in the propensity-matched group with respect to
eath (1.35% vs. 1.13%, p  0.14), CABG (1.14% vs. 0.90%,
 0.10), or transfusion (4.44% vs. 3.93%, p  0.08), but a
igher incidence of vascular complications was noted in pa-
ients treated with ACIS (2.63% vs. 1.84%, p  0.0002).
When we evaluated the outcome in the different
re-specified subgroups, a reduction in CIN with ACIS
m (ACIS) versus those treated with manual contrast injection.r syste
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403was identified in patients who were treated with iodix-
anol, whereas an increase in CIN was identified in
patients with moderately impaired renal function (Fig. 2).
The number of events was too low for a reliable subgroup
analysis for NRD.
Finally, when we assessed the renal outcomes in the
unmatched data (results not shown) or in the matched data
by stratifying patients by length of stay, there was no
difference in CIN among patients with length of stay of 2
days (0.52% vs. 0.65%, p  0.40), those discharged after a
Table 2. Baseline Characteristics of the Propensity-Matched Cohort of
Patients Treated With ACIS Versus Those Treated With Manual
Contrast Injection
Variable
ACIS
Frequency
(n  9,600)
Manual Injection
Frequency
(n  9,600)
Standardized
Difference
Age 60–69 yrs 28.8 28 1.77
Age 70–79 yrs 24.6 24.7 0.23
Age 80 yrs 11.4 12.1 2.17
Female 32.9 31.9 2.14
Overweight 35.3 35.9 1.25
Obese 47.6 45.0 5.22
Current smoking 28.5 29.8 2.86
Creatinine clearance 60–89 30.0 29.7 0.66
Creatinine clearance 30–59 18.1 18.9 2.06
Creatinine clearance 30 1.9 1.9 0
Hypertension 83.7 83.2 1.35
MI 32.9 32.9 0
Diabetes mellitus 33.5 33.5 2.13
Congestive heart failure 14.4 15.5 3.09
Extracardiac vascular
disease
26.1 26.8 1.59
Signiﬁcant valve disease 2.8 3.1 1.77
Chronic renal failure on
dialysis
1.7 1.9 1.5
Gastrointestinal bleeding 1.4 1.5 0.84
Atrial ﬁbrillation 9.9 11.2 4.23
Cardiac arrest 1.6 1.40 1.65
History of prior PCI 41.7 41.4 0.61
Prior CABG 18.7 19.6 2.29
Chronic obstructive
pulmonary disease
16.3 15.8 1.36
MI present (7 days prior) 31.7 32.2 1.07
Acute MI (24 h prior) 19.7 19.4 0.76
Cardiogenic shock 2.30 2.0 2.07
Cardiac arrest 1.7 1.6 0.79
Ventricular
tachycardia/ﬁbrillation
1.2 1.3 0.9
Emergent PCI 14.2 13.6 1.73
Baseline creatinine 1.5 mg/dl 11.2 11.2 0
Anemia 25.9 26.8 2.04
Ejection fraction 50% 28.7 28.2 1.11
Values are %.
Abbreviations as in Table 1.length of stay of 3 days (1.70% vs. 2.04%, p  0.52), and vthose whose hospital stay exceeded 3 days (10.25% vs.
12.22%, p  0.07).
Discussion
The key finding of our study is that use of ACIS in our
study population is not associated with a clinically mean-
ingful reduction in the volume of contrast media or in
reduction in the incidence of CIN or NRD. The outcomes
in patients treated with ACIS were broadly similar to those
in patients treated with manual injection and there was only
a marginal suggestion of benefit of 1 versus the other
strategy in certain subgroups.
Our findings are important for many reasons. Automated
contrast injector systems have been promoted as a means to
reduce the total amount of contrast used at a given institu-
tion and per patient. Although our study cannot evaluate the
amount of total contrast consumption at a given institution,
we did not find a clinically relevant reduction in contrast
dose for the average patients with ACIS. These findings call
into question the utility of the ACIS as a renal-protective
strategy.
The prior work related to use of ACIS is restricted to few
small studies, and the results were substantively different
from those observed in our study. Anne et al. (10) random-
ized 453 patients to manual injection versus ACIS and
found a substantial decrease in the amount of contrast used
for both patients who underwent diagnostic angiography
only (mean 130  60 ml vs. 257  64 ml) and those who
nderwent diagnostic catheterization and PCI (mean 228
0 ml vs. 350  94 ml). It is noteworthy that the average
mount of contrast used in the manual injection arm of this
tudy was significantly higher than the amount used in our
atient population. Furthermore, Brosh et al. (11) demon-
trated that the difference between the total amounts of
ontrast used was driven in large part by a difference in
mount of contrast wasted, although they also noted slightly
ower contrast administered to patients undergoing diagnos-
ic angiography with ACIS but not in those undergoing
CI. The impact of using ACIS on clinical outcomes was
ssessed by Call et al. (12). They compared the incidence of
IN among 1,798 patients treated at their institution over
2-year period before the introduction of ACIS with 377
atients who were treated after the introduction of ACIS.
hey noticed a decline in total contrast use from an average
f 204 to 146 ml and a corresponding decline in CIN from
9.3% to 13.3%.
The results of our study are in distinct contrast with the
ndings from these studies. The findings of our study
uggest that the old-fashioned manual injection is equally
ffective at controlling the amount of contrast use in this
atient population. Substantial reduction in the amount of
ontrast used/case requires forgoing procedures, such as left
entriculography or aortography, and limiting the total
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404number of contrast injections. It is unlikely that the total
amount used/injection can make a significant difference to
the total contrast use, provided the aforementioned mea-
sures are used. Finally, the BMC2 collaborative has been
engaged in a long-standing effort to reduce procedural
complications, including CIN, and it is possible that most
institutions and operators were actively working toward
minimizing contrast use. Such efforts would translate into
reduction in use of contrast in all patients and would
minimize any expected benefit of ACIS.
Although observational data in general cannot supplant
clinical trials, large studies such as ours can be helpful in
complementing randomized trials, particularly when the
randomized studies are small or reflect experience of select
centers. The results of our study suggest that institutional
use of ACIS does not automatically translate into a reduc-
tion in renal complications, and similar outcomes can be
obtained with manual injection. Automated contrast injec-
tor systems might have other benefits, such as allowing use
of smaller bore catheters for diagnostic angiography and
cost savings in association with reduction in total amount of
contrast used. However, the use of ACIS cannot be recom-
mended specifically for renal protection.
Our subgroup analysis did find significant differences in 2
groups of patients, a higher risk of CIN with ACIS in those
with a creatinine clearance of 30 to 60 ml/min/m2 and a
lower risk in those treated with iodixanol. The most likely
reason for this is that this simply reflects a chance finding,
because no adjustment for multiple comparisons was per-
formed. However, these subgroups might be worthy of
further study.
Study limitations. The BMC2-PCI registry is a regional
database with an active focus on multicentric quality im-
provement and might or might not be representative of the
wider population of patients undergoing PCI in the United
States (17). Nevertheless, the registry is comprehensive in
Figure 2. Subgroup Analysis
The propensity-matched odds of contrast-induced nephropathy among key su
system (ACIS) versus those treated with manual injection.that it includes almost all PCIs performed in the state ofMichigan. The study was also subject to unmeasured
residual confounding, despite propensity-matched analyses
that might influence any of the noted associations. We did
notice a difference in vascular complications in the
propensity-matched groups that might suggest differences
in practice or inability to fully adjust for patient-level
factors. There might be variance in other aspects of care,
such as differences in hydration policies, staging of proce-
dures, or use of left ventriculography or aortography across
the 2 hospital cohorts that were not adjusted for. Finally, the
term CIN implies that contrast media are solely responsible
for all cases of renal dysfunction occurring in this popula-
tion, although this is probably incorrect. We elected to use
this term, because there is no widely accepted alternative.
Conclusions
Compared with hospitals using manual injection, institu-
tions having ACIS used slightly lower amount of contrast
with no difference in CIN or NRD. Use of ACIS is unlikely
to impact contrast-induced renal complications in patients
undergoing PCI.
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